NCT03792503撤回4 期
Pemetrexed Plus Apatinib Maintenance Treatment in Patients With Non-squamous Non-small Cell Lung Cancer Patients Who Have Not Progressed After 4 Cycles of Induction Chemotherapy of Pemetrexed in Combination With Platinum-based Regimen: A Prospective, Open, One-arm Clinical Study
Xinqiao Hospital of Chongqing1 个研究点 分布在 1 个国家开始时间: 2019年2月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 撤回
- 发起方
- 试验地点
- 1
- 主要终点
- Progression free survival（PFS）
研究概览
简要总结
In order to further improve the therapeutic efficacy of advanced no-squamous non-small cell lung cancer patients, improve the life cycle, this study will take the standard after treatment pemetrexed combined other anti-angiogenesis drugs to maintain as the direction, so as to provide more over the evidence for the treatment of advanced NSCLC.
详细描述
In patients with advanced non-squamous non-small cell lung cancer, patients receiving pemetrexed and platinum-based chemotherapy after 4 cycles of non-progressive evaluation were treated with pemetrexed plus apatinib. Until the disease progresses, there are intolerable side effects or the patient requests to withdraw from the study. It is planned to include 20 subjects.
Dosing regimen： Apatinib 500mg po qd (If there is a 3-4 degree toxic side reaction after 14 days of administration, the dose can be lowered to 250mg qd); Pemetrexed 500 mg/m2 d1×q3w; Until the patient progresses, the toxicity is intolerable, the patient withdraws his knowledge, or the investigator judges that the medication must be discontinued.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Stage IV non-squamous non-small cell lung cancer diagnosed by pathology.
- •At least one measurable lesion.
- •If the genetic test (EGFR/ALK) is an EGFR-sensitive mutation or an ALK fusion gene-positive patient, it is necessary to receive targeted therapy for the first-line treatment; if there is no mutation, it is necessary to be a first-line patient.
- •Pemetrexed combined platinum induction chemotherapy after 4 cycles of RECIST curative effect evaluation of patients who were not progress.
- •Gender is not limited, age: ≥ 18 years old.
- •ECOG PS: 0-2 points.
- •Estimated lifetime ≥3 months
- •Organ function levels meet the following criteria:
- •Blood routine examination standards must meet: ANC≥1.5×109/L, PLT≥100×109/L, Hb≥100g/L (No blood transfusion and blood products within 14 days, not corrected by G-CSF and other hematopoietic stimulating factors).
- •Biochemical examination must be in accordance with the following criteria: TBIL<1.5×ULN, ALT, AST and ALP<2.5×ULN, BUN and Cr≤1×ULN or Endogenous creatinine clearance≥50ml/min (Cockcroft-Gault formula).
- •Women of childbearing age must have reliable contraceptive measures, or in the group of 7 days before the pregnancy test (serum or urine), and the results were negative, and willing to during the test and the last for 8 weeks after experimental drug using appropriate methods of contraception.For men, must be agreed to at the end of the experiments and tests of giving drugs after 8 weeks using appropriate methods of contraception or has sterilization surgery.
- •Subjects were willing to join in this study, signed informed consent, good adherence, cooperate with the follow-up.
排除标准
- •Squamous cell carcinoma (including adenosquamous carcinoma), small cell lung cancer (including small cell carcinoma and non-small cell mixed lung cancer).
- •Patient gene detection is EGFR sensitive mutation, or positive for ALK fusion gene.
- •Symptomatic brain metastasis (a patient with brain metastases who completed treatment and had stable symptoms 21 days before enrollment can be enrolled, but need to be confirmed by brain MRI, CT or venography to have no cerebral hemorrhage symptoms).
- •Imaging (CT or MRI) showed tumor lesions ranging from ≤ 5 mm to large vessels, or central tumors that invaded local large blood vessels; or showed significant pulmonary cavitary or necrotizing tumors.
- •Hypertension (systolic blood pressure ≥140 mmHg or diastolic blood pressure ≥90 mmHg) that is still uncontrollable using a combination of two antihypertensive drugs.
- •Have the following cardiovascular diseases: myocardial ischemia or myocardial infarction above grade II, poorly controlled arrhythmias (including men with QTc interval ≥ 450 ms, women ≥ 470 ms); according to NYHA criteria, grade III to IV cardiac insufficiency, Or cardiac color Doppler ultrasound examination indicates left ventricular ejection fraction (LVEF) <50%.
- •Patients with a history of pulmonary interstitial disease or a patient with pulmonary interstitial disease.
- •Abnormal coagulation (INR > 1.5 or prothrombin time (PT) > ULN + 4 seconds or APTT > 1.5 ULN), with bleeding tendency or undergoing thrombolysis or anticoagulant therapy.
- •There is obvious cough blood in the 2 months before enrollment, or the daily hemoptysis amount is 2.5ml or more.
- •Into the group of the first 3 months there have been significant clinical significance of bleeding symptoms or have definite bleeding tendency.
- •Events of arterial/venous thrombosis occurring within 12 months prior to enrollment, such as cerebrovascular accidents (including transient ischemic attacks, cerebral hemorrhage, cerebral infarction), deep vein thrombosis, and pulmonary embolism,etc.
- •Known hereditary or acquired bleeding and thrombophilia (such as hemophilia patients, coagulopathy, thrombocytopenia, hypersplenism, etc.)
- •Long-term unhealed wound or fracture.
- •Major surgery or severe traumatic injury, fracture or ulceration within 4 weeks of enrollment.
- •Factors that have a significant impact on oral drug absorption, such as inability to swallow, chronic diarrhea, and intestinal obstruction.
- •Abdominal fistula, gastrointestinal perforation or abdominal abscess occurred within 6 months prior to enrollment.
- •Urine routine indicates urinary protein ≥ ++, or confirmed 24-hour urine protein ≥ 1.0 g.
- •Has a history of psychiatric drugs abuse and can't quit or have a mental disorder.
- •Participated in other clinical trials of anti-tumor drugs within 4 weeks prior to enrollment.
- •Previous or concurrent with other unhealed malignant tumors, except for cured skin basal cell carcinoma, cervical carcinoma in situ, and superficial bladder cancer.
- •Pregnant or lactating women; those who have fertility are unwilling or unable to take effective contraceptive measures.
- •The investigator judges other conditions that may affect the conduct of the clinical study and the determination of the results of the study.
研究组 & 干预措施
Apatinib，Pemetrexe
Experimental
Pemetrexe 500 mg/m2 d1×q3w; Apatinib 500 mg Po qd
干预措施: Apatinib (Drug)
Apatinib，Pemetrexe
Experimental
Pemetrexe 500 mg/m2 d1×q3w; Apatinib 500 mg Po qd
干预措施: Pemetrexed (Drug)
结局指标
主要结局
Progression free survival（PFS）
时间窗: Up to three years
From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to three years
次要结局
- Health related quality of life(Up to three years)
- Overall survival (OS)(Up to three years)
- Disease control rate(Up to three years)
- Objective response rate(Up to three years)
研究者
Jianguo Sun
Deputy director
Xinqiao Hospital of Chongqing
研究点 (1)
Loading locations...
相似试验
已完成
4 期
Pemetrexed in Maintenance in Patients With Impaired Renal Function, 2 Dose Calculation StrategiesNon-small Cell Lung CancerNCT03607149Centre Georges Francois Leclerc11
已完成
不适用
Low Dose Weekly Docetaxel Versus Pemetrexed in Previously Treated Advanced Non-Small-Cell Lung CancerNon Small Cell Lung CancerNCT01004601Chang Gung Memorial Hospital179
Unknown
1 期
Anlotinib Combined With Pemetrexed And Carboplatin as First-line Treatment in Advanced Nonsquamous NSCLCNon-squamous Cell Non-Small Cell Lung CancerNCT03790228Henan Cancer Hospital43
Unknown
2 期
Study of Anlotinib Combined With Pemetrexed in Patients With Advanced Nonsquamous NSCLCNon-squamous Cell Non-Small Cell Lung CancerNCT03778138Henan Provincial People's Hospital51
已完成
2 期
Neoadjuvant Pemetrexed, Carboplatin and Bevacizumab in Unresectable, Locally Advanced Lung AdenocarcinomaLung CancerNCT01588704Si-Yu Wang42